Observational studyBrain and behavior2026
Decreased Physical Activity as an Early Digital Biomarker in Huntington's Disease: A One-Year Observational Study.
Observational study in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decreased Physical Activity as an Early Digital Biomarker in Huntington's Disease: A One-Year Observational Study.Brain and behavior · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHuntington's disease (HD) is a neurodegenerative disorder characterised by motor dysfunction, cognitive impairment, and psychiatric disturbances. This study analyzed the relationship between clinical characteristics, sarcopenia, and physical activity (PA) levels in HD patients.
methodsA 1-year observational study was conducted with symptomatic, ambulatory HD patients, assessed at baseline and after 12 months. PA was monitored using a Fitbit Charge 4 activity tracker, and sarcopenia was determined through assessments of muscle strength, quantity, and physical performance. Participants were classified into two clusters based on age, motor (Unified HD Rating Scale), and cognitive function (Mini-Mental State Examination).
resultsWe included 33 subjects with HD, mean age 53 (40-60) years, 45.5% males, median TFC 9.5 (7-13). At baseline, Cluster 1 had better motor function, functional capacity, and less apathy with a positive trend for higher PA, compared with Cluster 2, which had a negative trend for decreased PA over time (p = 0.006). After 1 year, Cluster 1 showed a decrease in PA (p = 0.035), similar to Cluster 2. At baseline, 53% of participants in Cluster 2 presented probable or confirmed sarcopenia, compared with 13% in Cluster 1. Significant differences (p < 0.05) were observed in muscle strength, bioelectrical impedance analysis (BIA), and SPPB scores, with higher values in Cluster 1.
conclusionsThese preliminary findings suggest that a reduction in PA using wearable technology may be a potential early indicator of functional changes in HD. Identifying when PA reduction begins can help determine the timing of interventions aimed at delaying disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.